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a contributor to reduce risk of cardiovascular, cerebrovascular, and renal disease.
This study aims to examine how the Part D affects medication adherence to ang-
iotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers
(ARBs) for dual eligibles. METHODS: This is a retrospective study with an unbal-
anced panel design utilizing Medicaid Analytic eXtract (MAX) data for 2004-2005
and Medicare data for 2006-2007. The study population was dual eligibles who had
at least one claim on ACEIs or/and ARBs in eight states. Medication adherence was
measured as a Proportion of Days Covered (PDC) in each year from 2004-2007 (Ob-
servation number69,039). A separate analysis was conducted for community
based residents (Observation number54,266) and for nursing home residents (Ob-
servation number14,773). RESULTS: Unadjusted PDCs showed little difference
between pre-Part D and post-Part D program. Community based residents had a
PDC of 0.775 under pre-Part D and 0.782 under post-Part D. For nursing home
residents, a PDC was 0.813 under pre-Part D and 0.796 under post-Part D. This
finding was also supported by the regression analyses: Although Part D program
was positively associated with medication adherence, this was statistically insig-
nificant (p0.05). Non-white status, hospitalization, prescription drug based risk
adjustment, and residence of states were negatively associated with medication
adherence, and all of them were significant (p0.05). CONCLUSIONS: Contrary to
concerns from the public that that Part D program, delivered through private plans,
may have some negative effect on prescription drug uses for dual eligibles com-
pared to Medicaid program, we found no negative effect from the Part D on medi-
cation adherence to ACEIs or/and ARBs for dual eligibles.
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OBJECTIVES:TheCenters forMedicare andMedicaid Services (CMS) funded several
demonstration projects in 2006 to examine the role of patient navigation (PN) pro-
gram in increasing cancer screening and improving treatment outcomes. CMS paid
monthly capitated fees for PN services in these projects. Using Medicare beneficia-
ries diagnosed with lung cancer as an example, we evaluated the above Medicare
policy. METHODS:We designed a Markov model to describe the nature history of
the disease after a lung cancer diagnosis and evaluated the PN program from
payer’s perspective. The model characterized clinical benefits of PN services as
reduction in the delay of treatment, and survival benefit from better coordinated
care. Using costs and health utility (derived from EQ-5D) data collected from the
case (with PN services) and control (usual care) groups at the demonstration site led
by MD Anderson Cancer Center, supplemented with information from the litera-
ture, we estimated the life-time costs and quality-adjusted life years (QALYs) for
the PN and usual care groups, with a 3% discount rate. We addressed uncertainties
associated with modeling parameters in one-way as well as probabilistic sensitiv-
ity analyses. RESULTS:Compared to usual care, PN services incurred high costs but
also yielded better outcomes. The incremental cost and effectiveness was $6,295
and 0.285 QALYs, respectively, resulting in an ICER of $22,108/QALY. One-way sen-
sitivity analysis indicated that findings were most sensitive to a parameter that
captured the increase in utilization due to more frequently interaction with the
health care system driven by PN services. CE-acceptability curve showed that the
probability that the PN program was cost-effective was 63% and 93% at a societal
willingness-to-pay of $50,000 and $100,000/QALY, respectively. CONCLUSIONS:
Our case study of lung cancer suggested that instituting PN program is cost-effec-
tive for Medicare. Future research should evaluate whether the same conclusion
held in other cancers.
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OBJECTIVES: The purpose of this study is to quantify the perioperative outcomes,
complications, and costs associated with posterior spinal fusion among Medicare
enrollees with spinal stenosis and spondylolisthesis using a national Medicare
claims database. METHODS: The 5% systematic sample of Medicare claims data
(2005-2009) was used to identify outcomes of patients who received posterior spi-
nal fusion (PSF) for a diagnosis of lumbar spinal stenosis (LSS) or spondylolisthesis.
Enrollees further required aminimum of 2 years’ follow-up, and claim history of at
least 12 months prior to surgery. RESULTS: A final cohort of 1,672 PSF patients was
included. 50.7%had LSS only; 10.2%had spondylolisthesis only; and 39.1%had both
LSS and spondylolisthesis. The average agewas 71.4, and the average length of stay
was 4.6 days. At 3months, 1 year, and 2 years post-operative, the incidence of spine
reoperation was 19.9%, 24.0%, and 28.0%, respectively, while readmission for com-
plications was 34.5%, 41.4%, and 47.9%, respectively. 45.2% of patients had either a
spine reoperation or post-op epidural injection due to continued pain at 2 years.
The average payment was $36,230 / $17,020, $46,840 / $31,350, and $61,610
/ $46,580 at 3 months, 1 year, and 2 years, respectively. CONCLUSIONS: Over
half of the PSF-treated patients in this study had LSS alone, and 32% of stenosis-
only patients underwent fusion, suggesting that factors other than spondylolisthe-
sis play a significant role in the decision to recommend spinal fusion in this elderly
population. One in 4 elderly fusion patients being treated for LSS or spondylolis-
thesis was reoperated on the spine within 2 years, and nearly 1 in 2 readmitted for
a surgery-related complication. This data highlights several areas where improve-
ments can be made in the effective delivery and cost of surgical care for patients
with spinal stenosis and spondylolisthesis.
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OBJECTIVES: The famed ACCORD-Lipid Trial found that simvastatin/fenofibrate
combination therapy (CT) provides no incremental cardiovascular risk reduction in
type 2 diabetese (T2D) over statinmonotherapy (MT). Yet, with sales over $1 billion,
fibrate use in the US does not appear to have slowed down. The inconsistency
between scientific evidence and clinical practice raises concern. There is dearth of
longitudinal studies with longer follow-up evaluating the efficacy of CT over MT.
This study replicates the ACCORD-Lipid trial using a 16-year longitudinal claims
database froma large US health plan.METHODS:This retrospective study included
patients enrolled between 1995 and 2010. ACCORD inclusion/exclusion criteria
were adopted, that required, among other things, T2D patients on statinwith base-
line A1C7.5 and aged 40 to 79. The two study cohorts, MT and CT, were identified
from pharmacy claims. At a minimum, patients must have 1-year baseline and
90-day follow-up periods. Cox proportional hazard models were used on propen-
sity-score-matched sample to estimate the hazard of major adverse cardiac event
(MACE). Secondary ACCORD outcomes, described below, were also assessed.
RESULTS: The study included 9711 patients (MT8383; CT1328) with average
follow-up of 3.2 years. An average patient in the sample was a White male aged 57
years from the South with annual household income of $40-49K. The two study
cohorts differed in demographics (female, ethnicity, income), baseline lipid panel
(HDL/LDL/triglyceride/HbA1c), and comorbid conditions. CT and MT patients did
not differ in MACE rate (hazard rate or HR1.19), and in all-cause death (HR1.09),
macrovascular event(HR0.89), cardiovascular death(HR0.87), coronary disease
event(HR1.22), non-fatal stroke(HR1.09) and CHF event(HR1.04), all with non-
significant p-values. CONCLUSIONS:We found that, compared to MT, CT may not
provide any additional cardiovascular risk reduction in T2D. Given that our data-
base represents a large commercially-insured US population, our findings appear
to genearalize ACCORD-Lipid trial results to real-world population.
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OBJECTIVES: Pulmonary exacerbations (PEx) lead to substantial morbidity in cystic
fibrosis (CF), and guidelines recommend chronicmedication including dornase alfa
and inhaled tobramycin. However PEx risk and medication use vary across pa-
tients. We aimed to develop a PEx risk score among CF patients not receiving
guideline-recommended chronic respiratory medications. METHODS: Patients
without evidence of dornase alfa or inhaled tobramycin use in an index year, de-
spite meeting guideline recommended criteria, were identified from the CF Foun-
dation Patient Registry (2002 to 2008). This sample was randomly split into 2/3 for a
development sample and 1/3 for a validation sample. A multivariable risk score
was developed to predict PEx requiring hospitalization or home IV treatment using
available patient characteristics. Its predictive performance was assessed in the
validation sample. RESULTS:Among 3,069 patient-years, 1,275 (42%) had PEx in the
subsequent year. The risk score included, in order of decreasing impact on PEx risk,
prior PEx, Pseudomonas aeruginosa, allergic bronchopulmonary aspergillosis, de-
pression, methicillin-resistant Staphylococcus aureus, cystic fibrosis-related diabe-
tes, Burkholderia cepacia, prior use of dornase alfa, bronchodilator use, prior use of
inhaled tobramycin and lower FEV1 %-predicted. Stratifying patients by risk score
in the validation sample identified actual risks ranging from 14% in the lowest
decile to 90% in the highest. The c-statisticwas 0.8.CONCLUSIONS:APEx risk score
for CF patients not receiving guideline-recommended chronic therapieswas devel-
oped and validated, and identified patients with a wide range of risk. This score
could identify high-risk patients in whom chronic therapies should be initiated or
continued.
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OBJECTIVES: Previous studies indicated a higher risk of mortality with use of typ-
ical antipsychotics compared to atypical agents in diverse study populations. The
current study examined the risk of all-cause mortality among elderly dual eligible
beneficiaries (Medicaid and Medicare) using typical and atypical antipsychotics.
METHODS: A retrospective cohort study design matched on propensity score was
conducted using Medicare and Medicaid Analytical eXtract (MAX) data from four
states. The study population included elderly dual eligible beneficiaries (aged 65
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